These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34776944)

  • 1. Risk of Malignancy and Tuberculosis of Biological and Targeted Drug in Patients With Spondyloarthritis: Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Man S; Hu L; Ji X; Wang Y; Ma Y; Wang L; Zhu J; Huang F
    Front Pharmacol; 2021; 12():705669. PubMed ID: 34776944
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of infections of biological and targeted drugs in patients with spondyloarthritis: meta-analysis of randomized clinical trials.
    Hu L; Man S; Ji X; Wang Y; Liu X; Zhang J; Song C; Zhu J; Huang F
    Chin Med J (Engl); 2022 Apr; 135(8):911-919. PubMed ID: 35730370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of malignancies in patients with spondyloarthritis treated with biologics compared with those treated with non-biologics: a systematic review and meta-analysis.
    Kwan YH; Lim KK; Fong W; Goh H; Ng L; Haaland B; Phang JK; Low LL; Yeo JG; Huang F; Leung YY; Thumboo J; Østbye T
    Ther Adv Musculoskelet Dis; 2020; 12():1759720X20925696. PubMed ID: 33149771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials.
    Ji X; Hu L; Wang Y; Man S; Liu X; Song C; Zhang J; Zhu J; Zhang J; Huang F
    Chin Med J (Engl); 2022 Jan; 135(4):409-415. PubMed ID: 35194004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials.
    Xu Z; Xu P; Fan W; Yang G; Wang J; Cheng Q; Yu M
    Exp Ther Med; 2017 Oct; 14(4):3491-3500. PubMed ID: 29042938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Wang S; He Q; Shuai Z
    Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
    Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
    JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials.
    Roche D; Badard M; Boyer L; Lafforgue P; Pham T
    Arthritis Res Ther; 2021 Jul; 23(1):192. PubMed ID: 34271991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
    Bonovas S; Fiorino G; Allocca M; Lytras T; Nikolopoulos GK; Peyrin-Biroulet L; Danese S
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1385-1397.e10. PubMed ID: 27189910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis.
    Lopez-Olivo MA; Tayar JH; Martinez-Lopez JA; Pollono EN; Cueto JP; Gonzales-Crespo MR; Fulton S; Suarez-Almazor ME
    JAMA; 2012 Sep; 308(9):898-908. PubMed ID: 22948700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.
    Souto A; Maneiro JR; Salgado E; Carmona L; Gomez-Reino JJ
    Rheumatology (Oxford); 2014 Oct; 53(10):1872-85. PubMed ID: 24821849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis.
    Cruz-Machado AR; Rodrigues-Manica S; Silva JL; Alho I; Coelho C; Duarte J; Florêncio C; Pimentel-Santos FM; Tavares-Costa J; Vieira-Sousa E
    Rheumatology (Oxford); 2020 Nov; 59(11):3158-3171. PubMed ID: 32696064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis.
    Souto A; Salgado E; Maneiro JR; Mera A; Carmona L; Gómez-Reino JJ
    Arthritis Rheumatol; 2015 Jan; 67(1):117-27. PubMed ID: 25303044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative safety of biological treatment in patients with axial spondylarthritis: a meta-analysis of randomized controlled trials with placebo.
    Sun WT; He YH; Dong MM; Zhang YN; Peng KX; Zhang YM; Lin YD; Yang C; Peng PX
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):9824-9836. PubMed ID: 33090385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis.
    Thomas SS; Borazan N; Barroso N; Duan L; Taroumian S; Kretzmann B; Bardales R; Elashoff D; Vangala S; Furst DE
    BioDrugs; 2015 Aug; 29(4):241-58. PubMed ID: 26280210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
    Morice PM; Leary A; Dolladille C; Chrétien B; Poulain L; González-Martín A; Moore K; O'Reilly EM; Ray-Coquard I; Alexandre J
    Lancet Haematol; 2021 Feb; 8(2):e122-e134. PubMed ID: 33347814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
    Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis.
    Wang Q; Wen Z; Cao Q
    Exp Ther Med; 2016 Sep; 12(3):1693-1704. PubMed ID: 27588089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.